key: cord-0315248-19kvkxs5
authors: Lonati, P.; Bodio, C.; Scavone, M.; Martini, G.; Pesce, E.; Bandera, A.; Lombardi, A.; Gerosa, M.; Franceschini, F.; Tincani, A.; Podda, G.; Abrignani, S.; Grifantini, R.; Cattaneo, M.; Borghi, M. O.; Meroni, P. L.
title: The production of anti-PF4 antibodies in anti-phospholipid antibody-positive patients is not affected by COVID-19 vaccination
date: 2021-08-13
journal: nan
DOI: 10.1101/2021.08.12.21261976
sha: 106113346c04c46b34d643a13e36c7efa5a06454
doc_id: 315248
cord_uid: 19kvkxs5

Antibodies against cationic platelet chemokine, platelet factor 4 (PF4/CXCL4) have been described in heparin-induced thrombocytopenia (HIT) but also in patients positive for anti-phospholipid antibodies (aPL) even in the absence of heparin treatment and HIT-related clinical manifestations. Anti-PF4 antibodies have been recently described also in subjects who developed thrombosis with thrombocytopenia syndrome (TTS) in association with adenoviral vector-based, but not with mRNA-based COVID-19 vaccines. We investigated whether COVID-19 vaccination affects the production of anti-PF4 immunoglobulins detectable by solid-phase assay in aPL-positive patients and their ability to induce in vitro platelet activation. Anti-PF4 were found in 9/126 aPL-positive patients, 4/50 COVID-19, 9/49 other infections, and 1/50 aPL-negative systemic lupus erythematosus patients. Clinical manifestations of TTS were not observed in any aPL patient positive for anti-PF4, whose sera failed to cause platelet aggregations. The administration of COVID-19 vaccines did not affect the production of anti-PF4 immunoglobulins or their ability to cause platelet aggregation in 44 aPL-positive patients tested before and after vaccination. In conclusion, heparin treatment-independent anti-PF4 antibodies can be found in aPL-positive patients and asymptomatic carriers, but their presence, titer as well as in vitro effect on platelet activation are not affected by COVID-19 vaccination.

Anti-PF4 antibodies have been recently described also in subjects who developed thrombosis with thrombocytopenia syndrome (TTS) in association with adenoviral vector-based, but not with mRNAbased COVID-19 vaccines.

We investigated whether COVID-19 vaccination affects the production of anti-PF4 immunoglobulins detectable by solid phase assay in aPL-positive patients and their ability to induce in vitro platelet activation. Anti-PF4 were found in 9/126 aPL-positive patients, 4/50 COVID-19, 9/49 other infections and 1/50 aPL-negative systemic lupus erythematosus patients. Clinical manifestations of TTS were not observed in any aPL patient positive for anti-PF4, whose sera failed to cause platelet aggregations. The administration of COVID-19 vaccines did not affect the production of anti-PF4 immunoglobulins or their ability to cause platelet aggregation in 44 aPL-positive patients tested before and after vaccination. In conclusion, heparin treatment-independent anti-PF4 antibodies can be found in aPL-positive patients and asymptomatic carriers, but their presence, titer as well as in vitro effect on platelet activation are not affected by COVID-19 vaccination.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ;  https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint

Antibodies against cationic platelet chemokine, Platelet Factor 4 (PF4/CXCL4) have been reported in heparin-induced thrombocytopenia (HIT) but also in patients positive for anti-phospholipid antibodies (aPL) even in the absence of treatment with heparin and HIT-related clinical manifestations. [1] [2] [3] [4] [5] [6] [7] Despite the heterogeneity of published data, the majority of the studies reported the presence of anti-PF4 antibodies in up to 21% of aPL-positive samples, their heparin-dependent binding as in HIT but at lower titer and no effect on platelet activation.

Anti-PF4 antibodies have also been recently described in COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS). [8] [9] [10] [11] Although the hypothesis of a molecular mimicry between self-autoantigens and SARS-CoV-2 spike (S) protein is still debated, the active immunization with S protein was suggested to be responsible for the antibody response against PF4 as well. [12, 13] Accordingly, the issue of a potential danger of COVID-19 vaccination in aPL-positive patients was raised because of their thrombophilic state and the possible occurrence of anti-PF4 antibodies in some of them. With this in mind, we investigated whether COVID-19 vaccination affects the production of anti-PF4 antibodies in aPL-positive patients and their functional ability to induce in vitro platelet activation.

We investigated 126 aPL-positive samples including 71 primary anti-phospholipid syndrome (PAPS), 37 aPL-positive asymptomatic carriers, 18 APS associated with systemic autoimmune rheumatic disorders (SAPS). The diagnoses were made as previously described; [14] all samples displayed double or triple positivity for the APS laboratory classification criteria, [14] and medium/high titers of anti-cardiolipin and anti-beta2 glycoprotein I IgG/IgM.

As control groups the following samples were also tested: 50 COVID-19 patients with moderate disease as previously reported, [15] 49 individuals with non-COVID-19 infections (9 Epstein-Barr All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in [16] Nineteen PAPS, 12 aPL-positive asymptomatic carriers, and 13 SAPS were tested before and after COVID-19 vaccination (38 with Comirnaty, 2 with Spikevax, 3 with Vaxzevria, and 1 with Sputnik vaccine). Additional 2 PAPS patients were tested before and after full blown COVID-19 and positivity for SARS-CoV-2 nasopharyngeal swab. One-hundred fifty healthcare workers were also enrolled and serum samples were collected before and after vaccination by Comirnaty (100) or Vaxzevria (50).

Samples were collected before the second vaccine injection for both aPL-positive patients and healthcare workers (3 weeks after Comirnaty or Sputnik, 4 weeks after Spikevax and 12 weeks after Vaxzevria first injection, respectively).

The severe adverse side effects as defined by Polack et al. [17] or any clinical manifestation potentially correlated with the vaccination were also recorded for all the investigated patients or subjects.

The Ethics Committee at Istituto Auxologico Italiano approved the study (08-01-2021). All the patients/subjects gave their informed consent.

Anti-PF4 IgG/IgA/IgM were assessed by the polyspecific Lifecodes PF4 Enhanced ELISA (Immucor, Solihull, UK). The assay was performed according to the manufacturer's instructions, including negative and positive controls and confirmatory inhibition of the reaction in the presence of high concentrations of heparin (100 U/ml). Anti-PF4 antibodies are detectable in 1.0-4.3% of normal healthy subjects (NHS), depending on the commercial kit used. [18] Because of this variability of results, we used our in-house cut-off value of 0.80 optical density (OD) units, which was calculated as the mean + 3 SD of the results obtained in 189 NHS. Samples with binding values > 0.80 OD were re-tested in the presence of heparin (100 IU/mL) and for their ability to induce platelet aggregation (Platelet Aggregation Test, PAT). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint

PAT was performed using washed human platelet (WP) suspensions prepared as described [19] from ACD-anticoagulated blood from NHS and resuspended with Tyrode's solution without added CaCl2, containing 0.01 U/mL Apyrase from potatoes (Sigma-Aldrich, Taufkirchen, Germany). Heat inactivated (56°C, 30 min) serum was added to WP with buffer or heparin (0.2 and 100 IU/mL) (Veracer; Medic Italia, Milan, Italy). Platelet aggregation was measured in the PAP-8E Platelet Aggregation Profiler (Bio/Data Corporation, Horsham, PA, USA) for 30 min. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint

What is already known about this subject?

• Anti-PF4 antibodies have been described both in HIT and in aPL-positive patients independently from heparin treatment and HIT-related clinical manifestations.

• Anti-PF4 antibodies have been detected after the administration of adenoviral vector-based, but not mRNA-based COVID-19 vaccines and have been associated with TTS.

• Low-titer, heparin-dependent and PAT-negative anti-PF4 antibodies have been found in a small proportion of aPL-positive patients, as well as in aPL-negative SLE and infectious diseases.

• COVID-19 vaccination neither affects the titer of preexisting anti-PF4 antibodies in aPL-positive patients nor induces the ability of these antibodies to activate platelets in vitro.

• Vaccines against COVID-19 are seemingly safe and unable to induce the clinical and laboratory TTS-associated manifestation in aPL-positive patients.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint

There are no competing interests for any author. 

The paper was supported in part by Ricerca Corrente 2020 and 2021 -Ministero della Salute, Italyto PLM.

Patients and public were not involved in the design of the study. During the initial phases of the study, we obtained feedback from the patients. The results of the study will be disseminated in lay versions by Istituto Auxologico Italiano public relations and communications department for the benefit of the public.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint

False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus

Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome

False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus: a rebuttal

Tests for heparin-induced thrombocytopenia in primary antiphospholipid syndrome

Antiplatelet factor 4-heparin antibodies in patients with antiphospholipid antibodies

High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia

Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines

Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases

Vaccine-Induced Covid-19 Mimicry" Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Complement activation and endothelial perturbation parallel COVID-19 severity and activity

European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results

Preparation of suspensions of washed platelets from humans

Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.12.21261976 doi: medRxiv preprint